BioPharmaTrend
News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech
  • Interviews
  • Business Intelligence
  • Case Studies
Intelligence
  • Business Intelligence
  • Case Studies
  • Lab
  • Membership
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech
This company is included in Intelligence Lab

CytoReason

CytoReason logo

Website
http://www.cytoreason.com
Founded
2016

Technologies

AI Companies (Drug Discovery)

CytoReason turns human clinical data into clear biology, to deliver data-driven target discovery and drug development. CytoReason’s access to unmatched proprietary and public data, combined with cutting-edge machine learning technologies, creates our unique biological models of disease, tissue and drug. Using our molecular-level disease models we turn human clinical data into biology, mapping what the cells, genes and proteins are doing in a disease, tissue and treatment environment. This enables us to uncover disease and drug mechanisms of action and turn that biology into clinical edge, by delivering valuable IP in the form of novel targets, indications, combinations and biomarkers.

data mining drug discovery


Articles Mentioning This Company

How Big Pharma Adopts AI To Boost Drug Discovery

How Big Pharma Adopts AI To Boost Drug Discovery

Oct. 9, 2025     Articles
(Last updated: October 2025) Since 1950, when Alan Turing introduced the concept of 'thinking machines', artificial intelligence has steadily advanced—from the rise of neural networks in the 1980s to the release of OpenAI’s GPT-3 in 2020, which paved the way for ChatGPT in 2022. Today, AI has become an integral …

What Makes Israel's Life Sciences Ecosystem Successful?

Oct. 26, 2022     Articles
Israel's biotech sector has been considered secondary to its thriving Medtech field for decades. Still, the turn of millennia brought a significant shift to the biotech landscape in the country. Part of the growth originates from Israel’s focus on building a solid education with roughly 6% of GDP being spent on …

R&D Platform

The first cell-centered computational model of human disease

News

  • 2024-07-17
    CytoReason Secures $80 Million to Advance AI Disease Models

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • Business Intelligence
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Lab Access
  • Lab Membership
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.